Accepted Manuscript

Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R

Yu Wang, Shaowei Chen, Gang Hu, Jiao Wang, Wenfeng Gou, Daiying Zuo, Yucheng Gu, Ping Gong, Xin Zhai

PII: S0223-5234(17)30893-0

DOI: 10.1016/j.ejmech.2017.11.008

Reference: EJMECH 9883

To appear in: *European Journal of Medicinal Chemistry*

Received Date: 31 July 2017

Revised Date: 30 October 2017

Accepted Date: 3 November 2017

Please cite this article as: Y. Wang, S. Chen, G. Hu, J. Wang, W. Gou, D. Zuo, Y. Gu, P. Gong, X. Zhai, Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R, *European Journal of Medicinal Chemistry* (2017), doi: 10.1016/j.ejmech.2017.11.008.

Graphical abstract



Two series of 2,4-diarylaminopyrimidine (DAAP) analogues bearing thiazole or 1,2,3-triazole moieties were designed, synthesized and evaluated for their biological activity.